OncoVision Secures $40M Series B to Transform Cancer Imaging and Treatment

OncoVision, a trailblazer in advanced medical imaging devices for the diagnosis and treatment of cancer, is proud to announce a monumental funding milestone with a recent raise of $40,000,000. This infusion of capital underlines the market’s confidence in OncoVision’s innovative approach and steadfast commitment to transforming cancer care. With a dynamic global presence that spans over 30 markets through direct sales and trusted distributors—with strategic offices in Boston, USA and Valencia, Spain—OncoVision has consistently pushed the boundaries of what is possible in medical imaging. The company’s current clinical portfolio features revolutionary products such as Sentinella, the unique intra-operative Gamma Camera, and the groundbreaking MAMMI PET—a breast cancer diagnostic device with the unparalleled capability to visualize lesions smaller than 2mm and quantify tumor activity. In addition, OncoVision’s dedication to advancing preclinical research is evident with devices like Albira, while Wprobe remains the gold standard in radioguided surgery. The newly raised funds will be channelled towards bolstering the company’s robust internal product pipeline, further accelerating clinical and preclinical innovation to develop the next generation of technical and clinical solutions. This capital will enable increased research and development, streamline clinical trials, and expand OncoVision’s market footprint, ensuring that its cutting-edge products continue to deliver significant benefits to patients and healthcare providers alike. As OncoVision continues its journey of pioneering advancements in cancer imaging and treatment, this funding round marks an exciting new chapter in its mission to empower clinicians with best-performing, high-quality diagnostic tools and ultimately improve patient outcomes worldwide.